For a better browsing experience, we recommend using one of the following browsers:
On June 27th we will host at IEI senior representative from Debiopharm Innovation Fund , a sister company of Debiopharm Group which is a family-owned biopharmaceutical group of companies headquartered in Lausanne, Switzerland. Active in the life science areas of drug development, GMP manufacturing of proprietary drugs and diagnostic tools. 420 employees.
Debiopharm Innovation Fund's objective is to make strategic investments in innovative companies with technologies and business models that change the they develop drugs and treat patients.
Senior representatives from Debiopharm Innovation Fund will be having B2B meetings with several Israeli digital health companies in the field of Oncology and Infectious Disease to explore ways of cooperation and investment opportunities.